Elite 50% OFF Act now – get top investing tools Register Now!

Orchestra BioMed Holdings, Inc.

Contributing Author

Recent Articles by Orchestra BioMed Holdings, Inc.

Nov-11	Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences OBIO GlobeNewswire
Nov-10	Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates OBIO GlobeNewswire
Nov-03	Orchestra BioMed to Host Business Update Call on November 12, 2025 OBIO GlobeNewswire
Oct-28	Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements OBIO GlobeNewswire
Oct-27	Orchestra BioMed Announces First Patients Enrolled in Virtue SAB US Pivotal IDE Coronary Trial OBIO GlobeNewswire
Oct-09	Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit OBIO GlobeNewswire
Sep-04	Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout OBIO GlobeNewswire
Aug-26	Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology OBIO GlobeNewswire
Aug-14	Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction OBIO GlobeNewswire
Aug-12	Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates OBIO GlobeNewswire
Aug-08	Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility OBIO GlobeNewswire
Aug-05	Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings OBIO GlobeNewswire
Aug-01	Orchestra BioMed Announces Pricing of $40 Million Public Offering OBIO GlobeNewswire
Jul-31	Orchestra BioMed Announces Proposed Public Offering OBIO GlobeNewswire
Jul-31	Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed OBIO GlobeNewswire
Jun-18	Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025 OBIO GlobeNewswire
May-12	Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones OBIO GlobeNewswire
May-07	Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure OBIO GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.